Safety of using anti-TNF-α blockers in cardiac failure associated with systemic inflammatory disease and the risk of Kounis syndrome

Int J Cardiol. 2013 Sep 20;168(1):540-1. doi: 10.1016/j.ijcard.2013.01.244. Epub 2013 Feb 22.

Authors

Nicholas G Kounis¹, George D Soufras, George N Kounis

Affiliation

¹ Department of Medical Sciences, Patras Highest Institute of Education and Technology, Patras, Greece. Electronic address: [email protected].

PMID: 23434010
DOI: 10.1016/j.ijcard.2013.01.244

No abstract available

Keywords: Cardiac failure; Chimeric antibodies; Inflammatory disease; Kounis syndrome.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Heart Failure / drug therapy*
Heart Failure / epidemiology
Heart Failure / metabolism
Humans
Recombinant Fusion Proteins / adverse effects*
Risk Factors
Syndrome
Systemic Inflammatory Response Syndrome / chemically induced*
Systemic Inflammatory Response Syndrome / epidemiology
Systemic Inflammatory Response Syndrome / metabolism
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / metabolism

Substances

Antibodies, Monoclonal, Humanized
Recombinant Fusion Proteins
Tumor Necrosis Factor-alpha